H.C. Wainwright does not see direct read from Roche miss to Olema's OPERA-02 [Yahoo! Finance]
Olema Pharmaceuticals, Inc. (OLMA)
Company Research
Source: Yahoo! Finance
eliminated for palazestrant and does not believe the persevERA trial is “a complete readthrough” to Olema Oncology's ( OLMA ) OPERA-02 trial, which is evaluating palazestrant plus ribociclib. Differences in combo agents could favor OPERA-02, argues the analyst, who keeps a Buy rating on Olema shares. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now See the top stocks recommended by analysts Read More on OLMA: Disclaimer & Disclosure Report an Issue Olema Pharmaceuticals, Inc. (OLMA) Q4 Earnings Cheat Sheet Asymmetric Upside on Olema Ahead of Roche's persevERA Readout: Buy/High Risk Maintained on Palazestrant Optionality Olema Oncology initiated with a Buy at Stifel Olema Pharmaceuticals
Show less
Read more
Impact Snapshot
Event Time:
OLMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OLMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OLMA alerts
High impacting Olema Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
OLMA
News
- A Look At Olema Pharmaceuticals (OLMA) Valuation After Roche Breast Cancer Trial Setback And Share Price Pullback [Yahoo! Finance]Yahoo! Finance
- Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMABusiness Wire
- Olema Pharmaceuticals (OLMA) had its "buy" rating reaffirmed by TD Cowen.MarketBeat
- Olema Pharmaceuticals (OLMA) had its price target lowered by HC Wainwright from $45.00 to $38.00. They now have a "buy" rating on the stock.MarketBeat
- Olema Pharmaceuticals (OLMA) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..MarketBeat
OLMA
Earnings
- 11/10/25 - Miss
OLMA
Sec Filings
- 3/11/26 - Form 144
- 3/10/26 - Form 144
- 3/9/26 - Form 144
- OLMA's page on the SEC website